QUOTE AND NEWS
Market Intelligence Center  Oct 17  Comment 
The patented options-trade picking algorithms used by MarketIntelligenceCenter.com found a trading opportunity with Salix Pharmaceuticals (SLXP) that should provide a 10.86% return in just 92 days. Sell one Jan. '15 call at the $135.00 level for...
StreetInsider.com  Oct 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Salix+Pharma+%28SLXP%29+Reports+FDA+Approval+of+UCERIS+2mg+Rectal+Foam/9895586.html for the full story.
Benzinga  Oct 6  Comment 
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today received a $40 million milestone payment from its worldwide collaboration partner, Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP), upon the US Food and Drug Administration's approval last week of...
FiercePharma  Oct 3  Comment 
Chalk up a victory for the U.S. Treasury Department, whose new rules put the kibosh on Salix Pharmaceuticals' tax inversion deal for Cosmo's Irish unit. Instead, the North Carolina company is reportedly in talks to sell itself--but to Actavis, not...
StreetInsider.com  Oct 3  Comment 
RadioShack (NYSE: RSH ) 35.5% HIGHER; is said to have reached an agreement with a consortium led by Standard General with respect to a $590 million financing agreement. Rockwell Medical Technologies (NASDAQ: RMTI
TheStreet.com  Oct 3  Comment 
NEW YORK (TheStreet) -- Shares of Salix Pharmaceuticals Ltd. are up 3.71% to $156.70 in pre-market trade after it was reported that the companyais in talks to sell itself to Actavis Plc, , sources told Bloomberg, after it failed to reach a...
Wall Street Journal  Oct 3  Comment 
Salix Pharmaceuticals and the Italian parent company of Cosmo Technologies said they had terminated a merger agreement, amid a crackdown on so-called inversion deals.
New York Times  Oct 3  Comment 
Allergan, the maker of Botox, sought a $10 billion deal for Salix that would not have required shareholder approval, a move intended to derail a takeover effort by Valeant and Pershing Square.
Market Intelligence Center  Oct 2  Comment 
With bullish technical indicators and a 3 STARS (out of 5) hold ranking from Standard & Poor’s, Salix Pharmaceuticals (SLXP) could be an attractive play for investors according to MarketIntelligenceCenter.com's patented option-trade picking...




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing, and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases. The company has a number of products currently approved for sales. These include Colazal (balsalazide disodium) for the treatment of mild to moderate active ulcerative colitis, Azasan (azathioprine) immuno-suppressive therapy for renal homo-transplant rejection and rheumatoid arthritis, and Anusol/Proctocort (hydrocortisone) for the relief of inflammatory dermatoses and hemorrhoids. In May 2004, the company received final Food and Drug Administration (FDA) approval for Xifaxan (rifaximin), an oral antibiotic for the treatment of traveler's diarrhea. Salix Pharmaceuticals is working on additional indications for Xifaxan, as well as a granulated formulation of mesalamine a common treatment option for ulcerative colitis.

Salix subsequently added new products to its portfolio including Visicol, indicated for colon cleansing prior to colonoscopy OsmoPrep, a next-generation Visicol which was launched in June 2006 and MoviPrep, a liquid bowel cleansing agent which was launched in October 2006. While Visicol and OsmoPrep were acquired by the company through its merger with InKine Pharmaceutical, exclusive U.S. in-licensing rights for MoviPrep were acquired from Norgine B.V. Recent additions to the product portfolio include Sanvar IR, indicated for the treatment of acute esophageal variceal bleeding (EVB) two hospital-based products, Pepcid Oral Suspension (indicated for several gastrointestinal indications including the treatment of duodenal ulcer, benign gastric ulcer and gastroesophageal reflux disease) and Diuril Oral Suspension (an adjunctive therapy in edema associated with several conditions including hepatic cirrhosis), from Merck and metoclopramide Zydis, indicated for short term (4 12 weeks) therapy for adults with symptomatic documented gastroesophageal reflux who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastric stasis.

Salix focuses primarily on the U.S. pharmaceutical market, promoting its drugs through its specialized sales force. Management also seeks to form strategic alliances to market its products outside the U.S. in order to avoid the significant costs, risks, and infrastructure inherent in assembling an international sales force. Salix is located in Morrisville, NC and employs roughly 240 professionals.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki